Zilucoplan (Zilbrysq): The Self-Injectable Peptide That Blocks Complement in Myasthenia Gravis (June 23, 2026)
Table of Contents
A peptide that targets the immune system's demolition crew
Most of the peptides that dominate the headlines work on metabolism or the brain. Zilucoplan does something different: it shuts down a part of the innate immune system called the complement cascade. Complement is a chain reaction of blood proteins that helps the body destroy pathogens, but at the very end of that chain it builds a structure called the membrane attack complex (MAC) that punches holes in cell membranes. In several autoimmune diseases that demolition crew turns on the body's own tissue. Zilucoplan is a synthetic macrocyclic peptide — a small, ring-shaped chain of amino acids — engineered to grab complement component 5 (C5), the protein that sits right before that final, destructive step.
How it works: two locks on the terminal pathway
Zilucoplan binds C5 with high affinity and blocks it in two ways at once. First, it prevents the enzyme C5 convertase from cleaving C5 into C5a (a potent inflammatory signal) and C5b. Second, it binds C5b directly so that, even if any forms, it cannot link up with the next protein (C6) to start building the membrane attack complex. The result is a tight block on the terminal complement pathway. In anti-acetylcholine-receptor (anti-AChR) antibody-positive generalized myasthenia gravis, this matters because the disease damages the neuromuscular junction — the place where nerves tell muscles to contract — largely through complement. Stop the MAC, and you protect the junction.
What makes it different from the antibodies that came first
Zilucoplan is not the first complement C5 inhibitor. The monoclonal antibodies eculizumab and ravulizumab arrived years earlier and also block C5. The breakthrough with zilucoplan is the format. It is a small peptide rather than a large antibody, which means patients can give it to themselves as a once-daily subcutaneous injection at 0.3 mg/kg — at home, with a small needle — instead of going to an infusion center for intravenous dosing. For a chronic disease, that convenience is a meaningful part of the story, and it is one reason zilucoplan is cited as a proof point that peptide chemistry can deliver targeted, antibody-like precision in a self-administered drug.
The evidence: the RAISE phase 3 trial
Zilucoplan's approval rests on RAISE, a randomized, double-blind, placebo-controlled phase 3 trial published in Lancet Neurology in 2023. It enrolled 174 adults with anti-AChR-positive generalized myasthenia gravis, randomized to zilucoplan or placebo for 12 weeks. The trial met its primary endpoint: the least-squares mean change in the MG-ADL score (a standard measure of myasthenia symptoms in daily activities) was −4.39 with zilucoplan versus −2.30 with placebo, a placebo-corrected improvement of 2.09 points (p=0.0004). Secondary measures — the QMG and MGC scores — moved in the same direction. The open-label extension study, RAISE-XT, has since reported that the improvement is sustained over the longer term with a consistent safety profile.
Approval, and the safety trade-off you cannot ignore
On the strength of that data, the U.S. FDA approved zilucoplan (brand name Zilbrysq, from UCB) in October 2023, and the EMA followed in December 2023, for anti-AChR-positive generalized myasthenia gravis in adults. There is an important catch built into how complement works. Because the terminal complement pathway is part of how the body fights certain bacteria, blocking it raises the risk of serious, even fatal, meningococcal (Neisseria meningitidis) infection. Zilucoplan therefore carries a boxed warning, requires meningococcal vaccination before starting, and is dispensed through a restricted risk-management program. This is a prescription drug used under neurology supervision — not something to self-source.
Why it is worth watching in 2026
Zilucoplan keeps appearing in the 2026 literature for two reasons. Long-term extension and real-world data are clarifying how durable the benefit is and where complement inhibition fits alongside the newer FcRn-blocking drugs and the older anti-C5 antibodies. And a 2026 medicinal-chemistry account of its discovery has put a spotlight on how a macrocyclic peptide was optimized into a self-injectable drug — a template other programs are studying. For anyone tracking peptides beyond the metabolic and longevity headlines, zilucoplan is a reminder that some of the most consequential peptide drugs are quietly treating autoimmune disease. As always, it is an approved therapy for a specific, antibody-defined patient group, and the evidence here is about that group — not a general-purpose enhancement.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Howard JF et al. — Safety and efficacy of zilucoplan in generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023 Source
- [2] Zilucoplan: First Approval. Drugs 2024 (PMC) Source
- [3] Long-term safety and efficacy of zilucoplan: RAISE-XT open-label extension interim analysis. PMC Source
- [4] Discovery of Zilucoplan: A Complement C5 Inhibitor for AChR-Positive gMG. J Med Chem 2026 (PMC) Source
Related Articles
Motixafortide (Aphexda): The FDA-Approved Peptide Working in Cancer Care — and Why Not Every Peptide Is About Weight Loss (June 17, 2026)
Most peptide headlines are about weight loss. Motixafortide (Aphexda, BL-8040) is a different kind of story: an FDA-approved cyclic peptide used in cancer care to mobilize stem cells for transplant — and now being tested against pancreatic cancer. Here's how it works and why it matters.
Pluvicto (Lutetium-177 PSMA): The Targeted Radiation Drug Reshaping Prostate Cancer — and Is It Really a Peptide? (June 19, 2026)
Pluvicto (lutetium-177 vipivotide tetraxetan) is one of oncology's most talked-about 'peptide-targeted' drugs — a radioligand that delivers radiation straight to prostate-cancer cells. In 2026 the Phase 3 PSMAddition trial pushed it into earlier disease. Here is how it works, what the new data show, and why calling it a 'peptide' deserves an asterisk.
Davunetide (NAP): The Tau-Targeting Microtubule Peptide Getting a Second Act in 2026 (June 22, 2026)
Davunetide is an eight-amino-acid peptide that stabilizes microtubules and lowers tau phosphorylation. It failed a major tauopathy trial — and in 2026 it is back, aimed at a rare genetic disease. Here is what the research actually shows.